The company said, “Biodexa has experienced net losses and significant cash outflows from cash used in operating activities over the past years as ...

Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage ...

When will we know it’s the peak, they fret. “To ask what will trigger the next stock market crash is akin to asking which snowflake will trigger the avalanche,” says Peter Berezin, chief global ...

Upgrading myself, because consulting is an intellectual capital business. Upgrading the leadership team is important because that's going to generate me returns three times, four times or even 10 ...

Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR1 of over 3,100% Prenetics increases FY2025 revenue guidance range of $85 - $100 ...

Revenue of $17.7 million in the second quarter of 2025, an increase of 594.9% as compared to the second quarter of 2024. Gross profit of $7.3 million in the second quarter of 2025, an increase of ...